Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

We're cautious about Vertex Pharmaceuticals. Here are three reasons why we avoid VRTX and a stock we'd rather own. Founded in 1989 to focus on a broad range of diseases, Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close. We recently published a list of the 11 Best Pharma ...

Great. Well thanks very much, everyone, for joining us for our next session with Vertex. My name is Dave Risinger. For those of you who don't know me, I cover Diversified Biopharmaceuticals. And ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Jones Financial Companies Lllp increased its stake in Vertex Pharmaceuticals by 75.5% in Q4, now holding 2,468 shares valued at $994,000. Other institutional investors, including Dunhill Financial and ...